Key result
SGLT2 inhibitors improve heart failure outcomes regardless of diabetes status by targeting diabetic cardiomyopathy mechanisms.
Why the study?
The mechanism by which diabetic patients develop cardiomyopathy in the absence of hypertension, obesity, and dyslipidemia has been less studied, and the role of SGLT2 inhibitors in heart failure patients with or without diabetes is a recent breakthrough.
This review highlights the pathophysiology of diabetic cardiomyopathy and the therapeutic benefits of SGLT2 inhibitors in heart failure.
The relationship between diabetes and risk of heart failure has been described in previous trials, releasing the importance of the hyperglycemic state that, added to other risk factors, favors the development of coronary heart disease. The mechanism by which, in the absence of hypertension, obesity and/or dyslipidemia, diabetic patients develop cardiomyopathy has been less studied. Recently, the Sodium Glucose Co-transporter type 2 inhibitors (SGLT2 inhibitors) used for the treatment of heart failure patients with or without diabetes has been a breakthrough in the field of medicine. This review describes the established pathophysiology of diabetic cardiomyopathy and SGLT2 inhibitors, their mechanisms of action, and benefits in this group of patients.
No takes yet. Share an insight, caveat, or question.
Favaloro et al. (2021) conducted a review in Heart failure and diabetes. SGLT2 inhibitors was evaluated. SGLT2 inhibitors provide significant therapeutic benefits for the treatment of heart failure patients with or without diabetes by targeting the pathophysiology of diabetic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: